Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FIORINAL vs BREVITAL SODIUM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
FIORINAL is a combination of butalbital (barbiturate), aspirin (NSAID), and caffeine. Butalbital potentiates GABA-A receptor activity, producing sedative-hypnotic effects. Aspirin inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, which provides analgesic and antipyretic effects. Caffeine is a non-selective adenosine receptor antagonist, enhancing analgesic efficacy.
Brevital sodium (methohexital) is a barbiturate that acts as a GABA-A receptor agonist, enhancing chloride ion influx and hyperpolarizing neurons, leading to rapid sedation and anesthesia.
Relief of tension-type headache,Relief of migraine headache (off-label)
Induction and maintenance of general anesthesia,Adjunct to regional anesthesia,Short-duration surgical procedures
1-2 capsules (butalbital 50 mg, acetaminophen 300 mg, caffeine 40 mg) orally every 4 hours as needed, not exceeding 6 capsules per day.
Induction of anesthesia: 1-1.5 mg/kg IV bolus over 15 seconds; maintenance: 0.5-1 mg/kg IV bolus as needed or 50-150 mcg/kg/min IV infusion.
Butalbital 35-50 hours, aspirin 15-20 minutes (salicylate 2-3 hours at low doses, >20 hours at high doses), caffeine 3-5 hours. Prolonged in hepatic/renal impairment.
Terminal elimination half-life: 3–6 hours (mean ~4 hours); prolonged in hepatic impairment, obesity, or with repeated dosing due to redistribution.
Butalbital is extensively metabolized in the liver via hydroxylation and glucuronidation, primarily by CYP2C9 and CYP2C19. Aspirin is hydrolyzed to salicylic acid, then conjugated with glycine (salicyluric acid) and glucuronidated. Caffeine is metabolized by CYP1A2 to paraxanthine, theobromine, and theophylline.
Hepatic metabolism primarily by CYP2C9 and CYP3A4 to inactive metabolites; less than 1% excreted unchanged in urine.
Renal: 60% butalbital (mostly unchanged), 10% aspirin (salicylates, majorly as metabolites), 3% caffeine (metabolites and unchanged). Fecal: <5% overall.
Primarily hepatic biotransformation to inactive metabolites (mainly hydroxy-methohexital), with renal excretion of metabolites; less than 1% excreted unchanged in urine. Minor biliary/fecal elimination.
Butalbital 20-40% (albumin), aspirin 80-90% (albumin, concentration-dependent), caffeine 25-36% (albumin).
Approximately 70–90% bound to albumin.
Butalbital 0.8 L/kg, aspirin 0.15-0.2 L/kg, caffeine 0.6-0.8 L/kg. Indicates extensive tissue distribution for butalbital and caffeine.
Vd: 1.1–2.5 L/kg (mean ~1.5 L/kg). Larger Vd indicates extensive tissue distribution (highly lipophilic), leading to rapid redistribution and short duration after single bolus.
Oral: butalbital ~100%, aspirin 50-75% (first-pass metabolism), caffeine ~100%.
IV: 100%. IM: Not well established; likely >90%. Rectal: Variable, ~50–70% due to first-pass metabolism and incomplete absorption.
No specific guidelines; contraindicated in severe renal impairment (Cr Cl <30 m L/min) due to acetaminophen accumulation. Use with caution in moderate impairment.
No dosage adjustment required for GFR ≥10 m L/min; for GFR <10 m L/min, reduce dose by 50%.
Contraindicated in severe hepatic impairment (Child-Pugh Class C). For mild to moderate (Child-Pugh A or B), reduce dose by 50% or extend dosing interval.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: reduce dose by 75% or consider alternative.
Not recommended for pediatric use; safety and efficacy not established.
Induction: 1-2 mg/kg IV; maintenance: 0.5-1 mg/kg IV bolus or 50-150 mcg/kg/min IV infusion. Contraindicated in infants <2 months with stable BSA.
Start at lowest effective dose (e.g., 1 capsule every 4 hours) due to increased sensitivity to butalbital (sedation, confusion) and risk of acetaminophen hepatotoxicity; maximum daily acetaminophen dose 2 g.
Reduce induction dose by 50% and administer slowly over 60 seconds; maintenance infusion rates at lower end (50-100 mcg/kg/min).
None.
None.
Risk of Reye's syndrome in children with viral illness,Aspirin hypersensitivity (e.g., asthma, nasal polyps),Gastrointestinal bleeding and ulceration,Hepatic impairment due to butalbital metabolism,Caffeine overdose from excessive use,Dependence and withdrawal with prolonged butalbital use
Respiratory depression and apnea may occur; resuscitative equipment must be available,Hypotension and bradycardia possible; use with caution in patients with cardiovascular disease,Extravasation causes tissue necrosis; avoid intra-arterial injection,Seizures may occur in epileptic patients,Rapid injection may cause severe respiratory depression
Hypersensitivity to butalbital, aspirin, or caffeine,Active peptic ulcer disease,Hemophilia or bleeding disorders,Concomitant use of anticoagulants,Children with chickenpox or influenza-like symptoms (risk of Reye's syndrome),Severe hepatic or renal impairment,Porphyria
Known hypersensitivity to barbiturates,Porphyria (may precipitate acute attacks),Severe respiratory insufficiency,Status asthmaticus,Hypovolemic shock or severe hypotension
Avoid excessive caffeine intake from coffee, tea, energy drinks, or chocolate as it may compound caffeine's stimulant effects and increase anxiety or insomnia. Alcohol should be strictly avoided due to additive CNS depression and increased GI bleeding risk with aspirin. No specific food restrictions besides moderation of caffeine-containing foods.
No specific food interactions are documented for BREVITAL SODIUM. However, patients should avoid heavy meals before anesthesia due to risk of aspiration. Do not consume alcohol or grapefruit juice for 24 hours before and after administration, as they may alter drug metabolism and increase sedation.
First trimester: Butalbital is associated with neural tube defects, cleft palate; aspirin increases risk of gastroschisis, cardiac defects. Second trimester: Aspirin may cause premature closure of ductus arteriosus. Third trimester: Aspirin increases risk of intracranial hemorrhage, premature closure of ductus arteriosus; butalbital may cause neonatal withdrawal. Caffeine is not a major teratogen but high doses may increase miscarriage risk.
Teratogenic potential not fully established in humans. In animal studies, methohexital caused fetal resorptions and malformations at maternally toxic doses. First trimester: Avoid unless essential; risk of neural tube defects cannot be excluded. Second trimester: Limited data, but may cause fetal depression if used near delivery. Third trimester: Crosses placenta; may cause neonatal respiratory depression, hypotonia, and prolonged sedation. Use only if clearly needed with lowest effective dose.
Aspirin excreted in milk (M/P ratio ~0.03-0.3); risk of Reye syndrome. Butalbital excreted in low amounts; may cause neonatal sedation. Caffeine excreted (M/P ~0.5-0.7); may cause irritability. Avoid breastfeeding during chronic use.
Excretion into human milk unknown. M/P ratio not determined. Due to short half-life, minimal transfer expected after a single dose. Caution with repeated doses or prolonged infusion. Monitor infant for sedation, feeding difficulties, or respiratory depression.
Due to increased renal clearance and volume of distribution, butalbital may require dose increase; aspirin may need higher doses due to increased plasma volume; no specific adjustment for caffeine. Monitor clinical response and toxicity.
Pregnancy may increase volume of distribution and clearance, potentially requiring higher initial doses, but the induction dose typically unchanged. Reduced doses may be needed in preeclampsia or cesarean section due to enhanced sensitivity. No specific dose adjustment guidelines; titrate to effect with careful monitoring.
FIORINAL (butalbital/aspirin/caffeine) is a barbiturate-containing combination analgesic. Due to butalbital's high abuse potential and risk of withdrawal, it is reserved for tension-type headaches refractory to non-barbiturate therapies. Monitor for signs of barbiturate dependence, and limit quantity dispensed. Avoid in patients with porphyria, severe hepatic impairment, or hemorrhagic disorders (aspirin component). Caffeine may exacerbate anxiety or insomnia.
BREVITAL SODIUM (methohexital) is an ultrashort-acting barbiturate used for induction of anesthesia and for short procedures. Due to its rapid onset and brief duration, it requires careful titration. It is contraindicated in patients with porphyria. Extravasation causes tissue necrosis; administer only through a secure IV line. It lowers seizure threshold, but can also be used for electroconvulsive therapy (ECT) to induce seizures. Respiratory depression and hypotension are dose-dependent; have resuscitation equipment ready. Avoid in patients with severe hepatic impairment. Coadministration with opioids or benzodiazepines potentiates sedation and respiratory depression.
This medication contains butalbital, which can be habit-forming; do not exceed prescribed dose or duration.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they increase sedation and respiratory depression risk.,Do not drive or operate heavy machinery until you know how this drug affects you.,Take with food to reduce stomach upset; if you experience black or bloody stools, stop and seek immediate medical attention (signs of GI bleeding from aspirin).,Do not use more than directed; sudden discontinuation can cause withdrawal symptoms (anxiety, tremors, seizures).,Keep out of reach of children; overdose may be fatal.
BREVITAL SODIUM is a potent anesthetic that causes rapid loss of consciousness and should only be administered by trained medical professionals.,You may experience temporary pain or burning at the injection site; report any persistent pain or swelling to your healthcare provider.,Drowsiness, dizziness, and confusion may persist for several hours after the procedure; do not drive or operate machinery for at least 24 hours.,Avoid alcohol and other sedatives for 24 hours before and after the procedure as they may increase side effects.,Inform your doctor if you have a history of porphyria, liver disease, or drug allergies.,If you are pregnant or breastfeeding, discuss the risks and benefits with your healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FIORINAL vs BREVITAL SODIUM, answered by our medical review team.
FIORINAL is a Barbiturate Analgesic Combination that works by FIORINAL is a combination of butalbital (barbiturate), aspirin (NSAID), and caffeine. Butalbital potentiates GABA-A receptor activity, producing sedative-hypnotic effects. Aspirin inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, which provides analgesic and antipyretic effects. Caffeine is a non-selective adenosine receptor antagonist, enhancing analgesic efficacy.. BREVITAL SODIUM is a Barbiturate Anesthetic that works by Brevital sodium (methohexital) is a barbiturate that acts as a GABA-A receptor agonist, enhancing chloride ion influx and hyperpolarizing neurons, leading to rapid sedation and anesthesia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FIORINAL and BREVITAL SODIUM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FIORINAL is: 1-2 capsules (butalbital 50 mg, acetaminophen 300 mg, caffeine 40 mg) orally every 4 hours as needed, not exceeding 6 capsules per day.. The standard adult dose of BREVITAL SODIUM is: Induction of anesthesia: 1-1.5 mg/kg IV bolus over 15 seconds; maintenance: 0.5-1 mg/kg IV bolus as needed or 50-150 mcg/kg/min IV infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FIORINAL and BREVITAL SODIUM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FIORINAL is classified as Category C. First trimester: Butalbital is associated with neural tube defects, cleft palate; aspirin increases risk of gastroschisis, cardiac defects. Second trimester: Aspirin may cause prem. BREVITAL SODIUM is classified as Category C. Teratogenic potential not fully established in humans. In animal studies, methohexital caused fetal resorptions and malformations at maternally toxic doses. First trimester: Avoid . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.